Health ministry decides against including Itolizumab in clinical management protocols for COVID-19

The permission to market the drug was granted for the treatment of
cytokine release syndrome in 'moderate' to 'severe' Acute Respiratory
Distress Syndrome patients due to COVID-19.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/health-ministry-decides-against-including-itolizumab-in-clinical-management-protocols-for-covid-19/articleshow/77185259.cms

Comments

Popular posts from this blog

Clinical Database Management Professional Vacancy @ Teva

Pharma Production Executive Post Vacancy @ Intas

Biotecnika Times – Newsletter 28.02.2020 – DST Women Scientist WOS B, DBT-IOC Recruitment